n Owen PA, Castle DJ. Late-onset Schizophrenia: epidemiology, diagnosis, management and outcomes. Drugs & Aging 1999; 15 (2): 81-89.

21. Howard RJ, Graham C, Sham P et al. A controlled study of late-onset non-affective psychosis (late paraphrenia). Br J Psychiatry 1997; 170: 511-514.

22. Prager S, Jeste DV. Sensory impairment in late-life schizophrenia. Schizophr Bull 1993; 19: 755-772.

23. Pearlson GD, Kreger L, Rabins PV et al. A chart review study of late-onset and early-onset schizophrenia. Am J Psychiatry 1989; 146: 1568-1574.

24. Howard R, Rabins P, Seeman MV, Jeste DV, and The International Late-Onset Schizophrenia Group. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international Consensus. Am J Psychiatry 2000; 157: 172-178.

25. Hymas N, Naguib M, Levy R. Late paraphrenia a follow-up study. Int J Geriatr Psychiatry 1989; 4: 23-29.

26. Purohit DP, Perl DP, Haroutunian V et al. Alzhemer disease and related neurodegenerative diseases in ederly patients with schizophrenia: a post-mortem neuropathologic study of 100 cases. Arch Gen Psychiatry 1998; 55: 205-211.

27. Arnold SE, Trojanowsky JQ, Gur RE et al. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry 1998; 55: 205-211.

28. Lacro JP, Jeste DV. Geriatric Psychosis. Psychiatr Q 1997; 68: 247-260.

29. Christenson R, Blazer D. Epidemiology of persecutory ideation in an elderly population in the community. Am J Psychiatry 1984; 141: 1088-1091.

30. Greene JA, Asp J. The geriatric patients: a creative approach. J Tenn Med Assoc 1986; 78: 201-205.

31. Gurian BS, Wexler D, Baker EH. Late-life paranoia: possible association with early trauma and infertility. Int J Geriatr Psychiatry 7: 277-284.

32. Moore NC. Is paranoid illness associated with sensory deficits int he elderly? J Psychosom Res 1981; 25: 69-74.

33. Rockwell E, Krull AJ, Dimsdale J, Jeste DV. Late-onset psychosis with somatic delusions. Psychosomatics 1992; 35: 66-72.

34. Cooper AF, Curry AR. The pathology of deafness in the paranoid and affective psychoses of later life. J Psychosom Res 1976; 20: 97-105.

35. Winokur G. Delusional disorder. Comp Psychiatry 1977; 18: 511-521.

36. Kendler S, David KL. The genetics and biochemistry of paranoid schizophrenia and other paranoid psychosis. Schizophr Bull 1981; 7: 689-709.

37. Jorgenssen P. Classification and outcome in non-schizophrenic, non-affective delusional disorder. Psychopathology 1989; 22: 198-201.

38. Wragg R, Jeste DV. Neuroleptics and alternative treatments: management of behavioral symptoms and psychosis in Alzheimer’s disease and related conditions. Psychiatr Clin North Am 1988; 11 (1): 195-214.

39. Harris MJ, Panton D, Caligiuri MP, Krull AJ, Tran-Jhonson TK, Jeste DV. High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. Psychopharmacol Bull 1992; 28: 87-92.

40. Maixner SM, Mellow AM, Tandon R. The efficacy, safety and tolerability of antipsychotics in the elderly. J Clin Psychiatry 1999; 60 (8): 29-41.

41. Sweet RA, Pollock BG. New atypical antipsychotics. Experience and utility in the elderly. Drugs & Aging 1998; 12 (2): 115-127.

42. Sajatovic M, Ramírez LF, Vernon L, Brescan D, Simon M, Jurjus G. Outcome of risperidone therapy in elderly patients with chronic psychosis. Int J Psychiatry Med 26 1996; 3: 309-317.

43. Sajatovic M, Pérez D, Brescan D, Ramirez LF. Olanzapine therapy in elderly patients with schizophrenia. Psychopharmacol Bull 1998; 34 (4): 819-823.

44. Lane LM, Burns PR, Sanger TM, Beasley CM, Tollefson G. Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders. 11th European College of Neuropsychopharmachology Congress, Paris, October 31-November 4, 1998.

45. Madhusoodanan S, Brecher M, Brenner R, Kasckow J, Kunik M, Negron AE, Pomara N. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry 1999; 7 (2): 132-138.

46. Madhusoodanan S, Suresh P, Brenner R, Pillai R. Experience with the atypical antipsychotics-risperidone and olanzapine in the elderly. Ann Clin Psychiatry 1999; 11 (3): 113-8.

47. Madhusoodanan S, Brenner R, Suresh P, Concepción NM, Florita CD, Menon G, Kaur A, Nuñez G, Reddy H. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry 2000; 12 (1): 11-8.

48. Solomons K, Geiger O. Olanzapine use in the elderly: a retrospective analysis. Can J Psychiatry 2000; 45 (2): 151-5.

49. Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, Dose M, Barak Y, Haushofer M. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry 2000; 15 (6): 506-14.

50. Reznik I, Paleacu D. Risperidone and cognitive functioning in elderly schizophrenic patients. Am J Geriatr Psychiatry 2000; 8 (2): 177.

51. Wesnes K, Beuzen JN, Taylor N, Wood A. The effects of olanzapina and haloperidol on cognitive function in healthy elderly volunteers. J Psycho-pharmacol 1997; 11 (13): 152-158.

52. McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry 1999; 60 (5): 292-298.

53. Madhusoodanan S, Brenner R, Alcantra AJ. Clinical experience with quetiapine in elderly patients with psychotic disorders. Geriatr Psychiatry Neurol 2000; 13 (1): 28-32.

54. Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW. Long-Term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000; 22 (9): 1068-84.

55. Wilner KD, Tensfeldt TG, Baris B, Smolarek TA, Turncliff RZ, Colburn WA, Hansen RA. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol 2000; 49 (1): 15S-20S.

<< volver